Gene editing in sickle cell disease has moved from the laboratory to the clinic. In late 2023, regulators in the UK and the US approved the first CRISPR-based therapy, which edits a patient’s own blood stem cells so they produce high levels of fetal hemoglobin and stop sickling. It is a potentially curative, one-time treatment, but it is demanding: it requires high-dose chemotherapy, weeks in hospital, and a specialist center.
In this article I explain why sickle cell disease is such a natural target for gene editing, how the treatment works step by step, who may be eligible, and the questions I encourage patients to ask before deciding.
Why Sickle Cell Disease Suits Gene Editing
Sickle cell disease (SCD) is an inherited hematologic disorder caused by a single-letter change in the HBB gene on chromosome 11. This point mutation swaps the amino acid glutamic acid for valine at position 6 of the beta-globin chain, producing hemoglobin S (HbS).
When oxygen is low, HbS molecules polymerize into long fibers that distort red cells into rigid sickle shapes. These cells block small vessels, causing pain crises and organ damage, and they break down early, causing chronic hemolytic anemia.
Because the disease arises from one well-understood mutation, and because all blood cells come from hematopoietic stem cells in the bone marrow, fixing or bypassing the defect in those stem cells can, in principle, fix the blood for life.
How Gene Editing Works: The Main Approaches
Several strategies are approved or in development. They differ in what they change and how.
| Approach | What it does | Status |
|---|---|---|
| CRISPR-Cas9 to boost fetal hemoglobin | Disrupts the BCL11A enhancer, a genetic “off switch” for fetal hemoglobin in red cell precursors | Approved (exagamglogene autotemcel, Casgevy) |
| Lentiviral gene addition | Adds a modified, anti-sickling beta-globin gene using a viral vector; not strictly editing | Approved (lovotibeglogene autotemcel, Lyfgenia) |
| Base editing | Changes a single DNA letter without cutting both strands | In clinical trials |
| Direct mutation correction | Repairs the HBB mutation back to normal adult hemoglobin | Investigational |
Why fetal hemoglobin?
Fetal hemoglobin (HbF) is the form we make before birth. After infancy, the body largely switches it off. HbF does not sickle and actually interferes with HbS polymerization. Doctors have long observed that people who naturally keep high HbF levels have milder disease, and hydroxyurea works partly by raising HbF. Gene editing takes that principle much further.
CRISPR in plain language
CRISPR-Cas9 works like molecular scissors guided by a short RNA “address label.” The guide finds a precise DNA sequence, and the Cas9 enzyme cuts it. The cell’s own repair process then disables the targeted sequence, in this case the switch that silences fetal hemoglobin.
What the Treatment Involves, Step by Step
Gene editing for SCD is not a pill or a single injection. It is closer to a stem cell transplant using the patient’s own cells, so no donor is needed.
- Preparation: patients usually receive regular red cell transfusions for a few months beforehand to reduce HbS levels.
- Stem cell collection: a mobilizing drug (plerixafor) releases stem cells into the bloodstream, and they are collected by apheresis. G-CSF, used for other donors, is avoided because it can trigger crises in SCD.
- Manufacturing: the cells are edited in a specialized laboratory, which takes several weeks to months.
- Conditioning: the patient receives high-dose chemotherapy, typically busulfan, to clear space in the marrow.
- Infusion: the edited cells are returned through a vein, much like a blood transfusion.
- Recovery: patients stay in hospital, often for several weeks, until new blood counts recover, with transfusion and infection support.
Benefits, Risks and Who Qualifies
Potential benefits
In the trials that led to approval, most treated patients stopped having severe vaso-occlusive crises during follow-up, and hemoglobin levels rose. For people whose lives have been dominated by hospital admissions, that can be transformative.
Known risks and uncertainties
- Chemotherapy effects: busulfan causes low blood counts, mouth sores, infection risk and, very commonly, infertility. Fertility preservation should be discussed before treatment.
- Off-target effects: editing unintended DNA sites is a theoretical concern that requires long-term monitoring.
- Blood cancer risk: the lentiviral product carries a boxed warning about hematologic malignancy.
- Existing organ damage: damage already done to kidneys, lungs or brain is not reversed.
- Unknown long-term durability: follow-up is still measured in years, not decades.
Eligibility
Approved therapies are currently licensed for patients aged 12 and older with recurrent vaso-occlusive crises. Candidates need to be well enough to tolerate conditioning chemotherapy. Cost is very high, and access varies widely between countries and health systems.
How Gene Editing Fits With Other Treatments
Gene editing sits alongside, not in place of, established care. Most patients will still rely on hydroxyurea, transfusions, pain management, infection prevention with vaccines and penicillin in childhood, and newer disease-modifying drugs. Accurate diagnosis of sickle cell disease through hematological testing such as hemoglobin electrophoresis remains the starting point for every treatment decision.
Allogeneic bone marrow transplant from a matched sibling remains a well-established curative option, particularly for children. Gene therapy broadens the pool of people who might be cured, because it does not depend on finding a donor. Improvements in all of these approaches have steadily lengthened the life span of sickle cell patients. For a wider overview, see our sickle cell guide.
Key Takeaways
- Sickle cell disease is caused by a single mutation in the HBB gene, making it a strong target for gene therapy.
- The first approved CRISPR therapy switches fetal hemoglobin back on rather than correcting HbS directly.
- Treatment uses the patient’s own stem cells but requires myeloablative chemotherapy and a long hospital stay.
- Infertility and long-term unknowns are real trade-offs to weigh with your hematologist.
- Gene editing may prevent future crises, but it does not undo existing complications of sickle cell disease.
Frequently Asked Questions
Is gene editing a cure for sickle cell disease?
For many treated patients it appears to be functionally curative, with crises stopping after treatment. However, the patient still carries the original HBB mutation, can pass it to children, and long-term follow-up is still ongoing, so many specialists use the term “potentially curative.”
Does gene editing change my children’s genes?
No. Only blood stem cells are edited, not eggs or sperm. Your children inherit your original genes, so family planning and partner testing remain relevant.
How is gene editing different from a bone marrow transplant?
A standard transplant uses a donor’s stem cells and carries the risk of rejection and graft-versus-host disease. Gene therapy uses your own edited cells, avoiding those immune problems, but it still requires similar chemotherapy conditioning.
Can adults over 40 have gene therapy?
Age alone is not the only factor. Eligibility depends on disease severity, organ function and fitness for chemotherapy, and each center assesses candidates individually.
Will I still need hydroxyurea afterwards?
In most successful cases, disease-modifying drugs are no longer needed for crises. Your hematologist will continue to monitor blood counts and organ health, and some supportive treatments may continue.
